RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:2584

Classic mycosis fungoides

low confidenceDisorder

Also known as: Mycosis fungoides, Alibert-Bazin type

Publications

15,513

Trials

215

Interventional, condition-specific

Researchers

1,143

Distinct authors in sample

Gene link

—

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

A form of cutaneous T-cell lymphoma characterized by slow progression from patches to more infiltrated plaques and eventually to tumors. In classic mycosis fungoides (MF), extracutaneous involvement may occur.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (9)

CTCL/ mycosis fungoides · MF · cutaneous T-cell lymphoma/mycosis fungoides · mycosis fungoides · mycosis fungoides (morphologic abnormality) · mycosis fungoides NOS (morphologic abnormality) · mycosis fungoides of unspecified site · mycosis fungoides, Alibert-Bazin type · mycosis fungoides, unspecified site, extranodal and solid organ sites

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    15,513 matched papers (6,412 in last 10 years) Source

  3. Phenotype characterisedPresent

    37 HPO annotations (e.g. Dry skin; Skin rash; Abnormal lymphocyte morphology) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationPresent

    3 FDA designations (2 FDA orphan-indication approvals) — e.g. priliximab Source

  6. Interventional trialPresent

    215 matched on ClinicalTrials.gov (22 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

37

Associated phenotypes · MONDO:0009691

  • Dry skin
  • Skin rash
  • Abnormal lymphocyte morphology
  • Erythematous macule
  • Abnormal eyelid morphology

Showing 5 of 37 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

3

Designations · 2 with FDA orphan-indication approval

  • FDA priliximabMycosis Fungoides · 2017-09-18 · Not FDA Approved for Orphan Indication
  • FDA naloxoneMycosis Fungoides Pruritus · 2010-11-23 · Not FDA Approved for Orphan Indication
  • FDA brentuximab vedotin (Adcetris)Mycosis Fungoides · 2012-11-19

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

75

Drugs / clinical candidates · MONDO_0009691

CTD chemicals (MyDisease.info)

9 associated chemicals · 13 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.

  • Aminolevulinic Acid · therapeutic
  • Arsenic Trioxide · therapeutic
  • Carmustine · therapeutic
  • Etretinate · therapeutic
  • liposomal doxorubicin · therapeutic
  • Methoxsalen · therapeutic
  • metoprine · therapeutic
  • Trioxsalen · therapeutic
  • Vincristine · therapeutic

Pathways: Cytokine-cytokine receptor interaction; TNF signaling pathway; Adipocytokine signaling pathway; Amyotrophic lateral sclerosis (ALS); Cytokine Signaling in Immune system; Innate Immune System; Immune System; Signaling by Interleukins

MyDisease.info · MONDO:0009691

Literature

Is anyone studying this?

15,513

15,513 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

15,513 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

6,412 in the last 10 years · low confidence

Phrase hits: 15,513 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,143

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Geskin LJ7 papers · 2026

    Department of Dermatology, Columbia University Irving Medical Center, 161 Fort Washington Ave, 12th Floor, New York, NY, 10032, USA. ljg2145@cumc.columbia.edu.

    Papers in Europe PMC
  2. 02
    Sacknovitz Y6 papers · 2026

    Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.

    Papers in Europe PMC
  3. 03
    Assaf C5 papers · 2026

    Department of Dermatology, HELIOS Klinikum Krefeld, Academic Teaching Hospital of the University of Aachen, Germany.

    Papers in Europe PMC
  4. 04
    de Masson A5 papers · 2026

    French Cutaneous Lymphoma Group (GFELC), From Société Française de Dermatologie (SFD), Paris, France.

    Papers in Europe PMC
  5. 05
    Guenova E5 papers · 2026

    Department of Immunodermatology, Lausanne University Hospital, Lausanne, Switzerland; Department of Immunodermatology, Kepler University Hospital-Johannes Kepler University, Linz, Austria.

    Papers in Europe PMC
  6. 06
    Liu J5 papers · 2026

    Department of Dermatology and Venerology, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.

    Papers in Europe PMC
  7. 07
    Ortiz-Romero PL5 papers · 2026

    Department of Dermatology, Institute i+12, Hospital 12 de Octubre, Medical School, University Complutense, Madrid, Spain.

    Papers in Europe PMC
  8. 08
    Papadavid E5 papers · 2026

    Department of Dermatology, National and Kapodistrian University of Athens, National Centre for Rare Diseases-Cutaneous Lymphoma, Attikon University Hospital, Athens, Greece.

    Papers in Europe PMC
  9. 09
    Pileri A5 papers · 2026

    Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy.

    Papers in Europe PMC
  10. 10
    Quaglino P5 papers · 2026

    Dermatological Clinic, Department of Medical Sciences, University of Turin, Torino, Italy.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

215

interventional trials for this specific condition

215 interventional trials matched this specific condition name; 22 currently recruiting in our sample.

Data as of 11 September 2026

215 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 99.3th percentile).

low confidence · 99.3th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

215 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

30 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 5 · after dedupe 5 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 5 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (5)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Classic mycosis fungoides — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Classic mycosis fungoides" OR "Mycosis fungoides, Alibert-Bazin type" OR "CTCL/ mycosis fungoides" OR "cutaneous T-cell lymphoma/mycosis fungoides" OR "mycosis fungoides" OR "mycosis fungoides (morphologic abnormality)" OR "mycosis fungoides NOS (morphologic abnormality)" OR "mycosis fungoides of unspecified site" OR "mycosis fungoides of the unspecified site" OR "mycosis fungoides, unspecified site, extranodal and solid organ sites"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Classic mycosis fungoides" OR "Mycosis fungoides, Alibert-Bazin type" OR "CTCL/ mycosis fungoides" OR "cutaneous T-cell lymphoma/mycosis fungoides" OR "mycosis fungoides" OR "mycosis fungoides (morphologic abnormality)" OR "mycosis fungoides NOS (morphologic abnormality)" OR "mycosis fungoides of unspecified site" OR "mycosis fungoides of the unspecified site" OR "mycosis fungoides, unspecified site, extranodal and solid organ sites"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 215 interventional · 30 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: MF

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (15513) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-26T20:36:26.638Z